We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Puma Biotechnology, Inc. (PBYI - Free Report) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history. It missed estimates in two of the trailing four quarters, met expectations in one and surpassed the same in the other. The company had an average negative surprise of 2.98% in the last four quarters.
Puma’s shares have outperformed the Zacks classified Medical-Biomedical and Genetics industry, year to date. Shares of the company gained 17.9% so far this year, while the industry recorded an increase of 6%.
Let’s see how things are shaping up for this announcement.
Factors at Play
Being a development-stage company, Puma Biotech does not have any approved product in its portfolio. Thus, investor focus should remain on updates pertaining to the development of neratinib.
Puma Biotech has made significant progress with its lead candidate, neratinib. The candidate is currently under review in both the U.S. and the EU for the extended adjuvant treatment of HER2-positive early-stage breast cancer that has previously been treated with Herceptin-based adjuvant therapy.
We note that several phase II combination studies on neratinib for the treatment of breast cancer are currently underway.
In Dec 2016, Puma presented encouraging additional data from breast cancer studies at the San Antonio Breast Cancer Symposium (SABCS). These include data from HER2-positive early-stage breast cancer using loperamide and budesonide prophylaxis study; the FB-7 neoadjuvant HER2-positive breast cancer study in the subgroup of patients who are MammaPrint High; and data from neratinib plus AstraZeneca’s (AZN - Free Report) Faslodex in patients with HER2 non-amplified breast cancer with a HER2 mutation.
Earnings Whispers
Our proven model does not conclusively show that Puma Biotech is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of $2.02. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Puma Biotech’s carries a Zacks Rank #3. Though a favorable Zacks Rank increases the predictive power of ESP, the company’s 0.00% Earnings ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that this have the right combination of elements to post an earnings beat this quarter.
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) has an Earnings ESP of +18.18% and a Zacks Rank #3. The company is scheduled to release fourth-quarter results on Mar 2.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
Puma Biotechnology, Inc. (PBYI - Free Report) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history. It missed estimates in two of the trailing four quarters, met expectations in one and surpassed the same in the other. The company had an average negative surprise of 2.98% in the last four quarters.
Puma Biotechnology Inc Price and EPS Surprise
Puma Biotechnology Inc Price and EPS Surprise | Puma Biotechnology Inc Quote
Puma’s shares have outperformed the Zacks classified Medical-Biomedical and Genetics industry, year to date. Shares of the company gained 17.9% so far this year, while the industry recorded an increase of 6%.
Let’s see how things are shaping up for this announcement.
Factors at Play
Being a development-stage company, Puma Biotech does not have any approved product in its portfolio. Thus, investor focus should remain on updates pertaining to the development of neratinib.
Puma Biotech has made significant progress with its lead candidate, neratinib. The candidate is currently under review in both the U.S. and the EU for the extended adjuvant treatment of HER2-positive early-stage breast cancer that has previously been treated with Herceptin-based adjuvant therapy.
We note that several phase II combination studies on neratinib for the treatment of breast cancer are currently underway.
In Dec 2016, Puma presented encouraging additional data from breast cancer studies at the San Antonio Breast Cancer Symposium (SABCS). These include data from HER2-positive early-stage breast cancer using loperamide and budesonide prophylaxis study; the FB-7 neoadjuvant HER2-positive breast cancer study in the subgroup of patients who are MammaPrint High; and data from neratinib plus AstraZeneca’s (AZN - Free Report) Faslodex in patients with HER2 non-amplified breast cancer with a HER2 mutation.
Earnings Whispers
Our proven model does not conclusively show that Puma Biotech is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of $2.02. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Puma Biotech’s carries a Zacks Rank #3. Though a favorable Zacks Rank increases the predictive power of ESP, the company’s 0.00% Earnings ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that this have the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) is scheduled to release fourth-quarter results on Mar 1. The company has an Earnings ESP of +20% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) has an Earnings ESP of +18.18% and a Zacks Rank #3. The company is scheduled to release fourth-quarter results on Mar 2.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>